Integration of Food Animal Residue Avoidance Databank (FARAD) empirical methods for drug withdrawal interval determination with a mechanistic population-based interactive physiologically based pharmacokinetic (iPBPK) modeling platform: example for flunixin meglumine administration
暂无分享,去创建一个
Miao Li | Jim E Riviere | Lisa A Tell | Ronald E Baynes | Thomas W Vickroy | Yi-Hsien Cheng | Jason T Chittenden | Jennifer L Davis | Zhoumeng Lin | J. Riviere | L. Tell | Yi-Hsien Cheng | Zhoumeng Lin | Miao Li | Jennifer L. Davis | R. Baynes | T. Vickroy
[1] Malcolm Rowland,et al. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective , 2018, Clinical pharmacology and therapeutics.
[2] R. Gehring,et al. Mathematical modeling and simulation in animal health - Part II: principles, methods, applications, and value of physiologically based pharmacokinetic modeling in veterinary medicine and food safety assessment. , 2016, Journal of veterinary pharmacology and therapeutics.
[3] Barbara A. Wetmore,et al. Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments , 2018, Journal of Exposure Science & Environmental Epidemiology.
[4] J. Riviere,et al. Population pharmacokinetics in veterinary medicine: potential use for therapeutic drug monitoring and prediction of tissue residues. , 1998, Journal of veterinary pharmacology and therapeutics.
[5] K. Odensvik. Pharmacokinetics of flunixin and its effect on prostaglandin F2 alpha metabolite concentrations after oral and intravenous administration in heifers. , 1995, Journal of veterinary pharmacology and therapeutics.
[6] T. Maurer,et al. A Mechanistic Pharmacokinetic Model for Liver Transporter Substrates Under Liver Cirrhosis Conditions , 2015, CPT: pharmacometrics & systems pharmacology.
[7] Harvey J Clewell,et al. The use of Markov chain Monte Carlo uncertainty analysis to support a Public Health Goal for perchloroethylene. , 2007, Regulatory toxicology and pharmacology : RTP.
[8] T. Eissing,et al. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals , 2016, Clinical Pharmacokinetics.
[9] S. Jaiswal,et al. Role of enterohepatic recirculation in drug disposition: cooperation and complications , 2016, Drug metabolism reviews.
[10] M. Delp,et al. Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.
[11] R. Gehring,et al. Pharmacokinetics of Mequindox and Its Marker Residue 1,4-Bisdesoxymequindox in Swine Following Multiple Oral Gavage and Intramuscular Administration: An Experimental Study Coupled with Population Physiologically Based Pharmacokinetic Modeling. , 2017, Journal of agricultural and food chemistry.
[12] R. Gehring,et al. A framework for meta-analysis of veterinary drug pharmacokinetic data using mixed effect modeling. , 2015, Journal of pharmaceutical sciences.
[13] Harvey J Clewell,et al. Use of a Physiologically Based Pharmacokinetic Model to Identify Exposures Consistent With Human Biomonitoring Data for Chloroform , 2006, Journal of toxicology and environmental health. Part A.
[14] Rebecca A Clewell,et al. Pharmacokinetics of toxic chemicals in breast milk: use of PBPK models to predict infant exposure. , 2002, Environmental health perspectives.
[15] J Wojciechowski,et al. Interactive Pharmacometric Applications Using R and the Shiny Package , 2015, CPT: pharmacometrics & systems pharmacology.
[16] Walter Schmitt,et al. Development and Evaluation of a Generic Physiologically Based Pharmacokinetic Model for Children , 2006, Clinical pharmacokinetics.
[17] Y. Hu,et al. Pharmacokinetics of Flunixin Meglumine After Intravenous and Intramuscular Administration in Pigs , 2007 .
[18] Robert G. Pearce,et al. httk: R Package for High-Throughput Toxicokinetics. , 2017, Journal of statistical software.
[19] J. Thiry,et al. Evaluation of flunixin meglumine pour-on administration on prostaglandin E2 concentration in inflammatory exudate after induction of inflammation in cattle. , 2017, Research in veterinary science.
[20] Andrew Worth,et al. Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications , 2017, Regulatory toxicology and pharmacology : RTP.
[21] C. Maltecca,et al. The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine. , 2014, Journal of veterinary pharmacology and therapeutics.
[22] J. Fisher,et al. Application of Physiologically Based Absorption Modeling to Characterize the Pharmacokinetic Profiles of Oral Extended Release Methylphenidate Products in Adults , 2016, PloS one.
[23] G. Smith,et al. Pharmacokinetics of flunixin meglumine in swine after intravenous dosing. , 2006, Journal of veterinary pharmacology and therapeutics.
[24] Jim E Riviere,et al. Guide to FARAD resources: historical and future perspectives. , 2017, Journal of the American Veterinary Medical Association.
[25] M. Laurentie,et al. A physiologically based pharmacokinetic model for chickens exposed to feed supplemented with monensin during their lifetime , 2017, Journal of veterinary pharmacology and therapeutics.
[26] K. Odensvik,et al. High-performance liquid chromatography method for determination of flunixin in bovine plasma and pharmacokinetics after single and repeated doses of the drug. , 1995, American journal of veterinary research.
[27] Board on Agriculture. The use of drugs in food animals , 2013 .
[28] A. Craigmill. A physiologically based pharmacokinetic model for oxytetracycline residues in sheep. , 2003, Journal of veterinary pharmacology and therapeutics.
[29] H. E. Buist,et al. Characterization and application of physiologically based pharmacokinetic models in risk assessment , 2010 .
[30] R. Gehring,et al. Pharmacokinetics and tissue elimination of flunixin in veal calves. , 2016, American journal of veterinary research.
[31] R. Gehring,et al. Avoiding violative flunixin meglumine residues in cattle and swine. , 2017, Journal of the American Veterinary Medical Association.
[32] Harvey J Clewell,et al. Development and specification of physiologically based pharmacokinetic models for use in risk assessment. , 2008, Regulatory toxicology and pharmacology : RTP.
[33] Raymond S. H. Yang,et al. Physiologically based pharmacokinetic (PBPK) models for lifetime exposure to PCB 153 in male and female harbor porpoises (Phocoena phocoena): model development and evaluation. , 2010, Environmental science & technology.
[34] Yu-Mei Tan,et al. Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making , 2018, Toxicological sciences : an official journal of the Society of Toxicology.
[35] Q. Zheng,et al. Comment on: “A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood” , 2015, Clinical Pharmacokinetics.
[36] Hea‐Young Cho,et al. Sex-specific risk assessment of PFHxS using a physiologically based pharmacokinetic model , 2018, Archives of Toxicology.
[37] J. Riviere,et al. Development of a physiologic-based pharmacokinetic model for estimating sulfamethazine concentrations in swine and application to prediction of violative residues in edible tissues. , 2005, American journal of veterinary research.
[38] Z. Zeng,et al. Use of a Monte Carlo analysis within a physiologically based pharmacokinetic model to predict doxycycline residue withdrawal time in edible tissues in swine , 2012, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.
[39] Weihsueh A. Chiu,et al. Applying a Global Sensitivity Analysis Workflow to Improve the Computational Efficiencies in Physiologically-Based Pharmacokinetic Modeling , 2018, Front. Pharmacol..
[40] J. Fisher,et al. A physiologically based pharmacokinetic model for atrazine and its main metabolites in the adult male C57BL/6 mouse. , 2011, Toxicology and applied pharmacology.
[41] Harvey J Clewell,et al. Evaluating placental transfer and tissue concentrations of manganese in the pregnant rat and fetuses after inhalation exposures with a PBPK model. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.
[42] Shiew-Mei Huang,et al. Use of Physiologically Based Pharmacokinetic Modeling to Evaluate the Effect of Chronic Kidney Disease on the Disposition of Hepatic CYP2C8 and OATP1B Drug Substrates , 2018, Clinical pharmacology and therapeutics.
[43] R. Gehring,et al. Probabilistic Physiologically Based Pharmacokinetic Model for Penicillin G in Milk From Dairy Cows Following Intramammary or Intramuscular Administrations , 2018, Toxicological sciences : an official journal of the Society of Toxicology.
[44] Malcolm Rowland,et al. Physiologically-based pharmacokinetics in drug development and regulatory science. , 2011, Annual review of pharmacology and toxicology.
[45] H. Kindahl,et al. Pharmacokinetics and Pharmacodynamic Effects of Flunixin after Intravenous, Intramuscular and Oral Administration to Dairy Goats , 2003, Acta veterinaria Scandinavica.
[46] Jim E Riviere,et al. Performance Assessment and Translation of Physiologically Based Pharmacokinetic Models From acslX to Berkeley Madonna, MATLAB, and R Language: Oxytetracycline and Gold Nanoparticles As Case Examples. , 2017, Toxicological sciences : an official journal of the Society of Toxicology.
[47] J. Riviere,et al. Tabulation of FARAD Comparative and Veterinary Pharmacokinetic Data , 2006 .
[48] J. Coetzee,et al. The pharmacokinetics of transdermal flunixin meglumine in Holstein calves. , 2016, Journal of veterinary pharmacology and therapeutics.
[49] Jason T Chittenden,et al. Assessment of penetrant and vehicle mixture properties on transdermal permeability using a mixed effect pharmacokinetic model of ex vivo porcine skin , 2016, Biopharmaceutics & drug disposition.
[50] C. Liao,et al. Assessing exposure risks for freshwater tilapia species posed by mercury and methylmercury , 2016, Ecotoxicology.
[51] Kevin McNally,et al. A Workflow for Global Sensitivity Analysis of PBPK Models , 2011, Front. Pharmacol..
[52] L. Tell,et al. Use of population pharmacokinetic modeling and Monte Carlo simulation to capture individual animal variability in the prediction of flunixin withdrawal times in cattle. , 2013, Journal of veterinary pharmacology and therapeutics.
[53] R. Gehring,et al. Development and application of a multiroute physiologically based pharmacokinetic model for oxytetracycline in dogs and humans. , 2015, Journal of pharmaceutical sciences.
[54] J. Riviere,et al. Comparison of ELISA and LC-MS/MS for the measurement of flunixin plasma concentrations in beef cattle after intravenous and subcutaneous administration. , 2013, Journal of agricultural and food chemistry.
[55] R. Gehring,et al. Effect of formulation and route of administration on tissue residues and withdrawal times. , 2005, Journal of the American Veterinary Medical Association.
[56] W. Chou,et al. Bayesian evaluation of a physiologically based pharmacokinetic (PBPK) model for perfluorooctane sulfonate (PFOS) to characterize the interspecies uncertainty between mice, rats, monkeys, and humans: Development and performance verification. , 2019, Environment international.
[57] Zhoumeng Lin,et al. Human Food Safety Implications of Variation in Food Animal Drug Metabolism , 2016, Scientific Reports.
[58] J. Riviere,et al. Development of a physiologically based pharmacokinetic model for flunixin in cattle (Bos taurus) , 2014, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.
[59] J. Riviere,et al. Use of Probabilistic Modeling within a Physiologically Based Pharmacokinetic Model To Predict Sulfamethazine Residue Withdrawal Times in Edible Tissues in Swine , 2006, Antimicrobial Agents and Chemotherapy.
[60] Jiqiang Guo,et al. Stan: A Probabilistic Programming Language. , 2017, Journal of statistical software.
[61] Anna K. Johnson,et al. Pharmacokinetics of flunixin meglumine in mature swine after intravenous, intramuscular and oral administration , 2013, BMC Veterinary Research.
[62] Frédéric Y Bois,et al. Physiologically based modelling and prediction of drug interactions. , 2010, Basic & clinical pharmacology & toxicology.
[63] P. Toutain,et al. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed‐effects to characterize and quantify variability in drug pharmacokinetics , 2018, Journal of veterinary pharmacology and therapeutics.
[64] G. Smith,et al. Plasma pharmacokinetics and milk residues of flunixin and 5-hydroxy flunixin following different routes of administration in dairy cattle. , 2012, Journal of dairy science.
[65] M. Roberts,et al. Mathematical Models for Topical and Transdermal Drug Products , 2014 .
[66] Brad Reisfeld,et al. Characterizing the Effects of Race/Ethnicity on Acetaminophen Pharmacokinetics Using Physiologically Based Pharmacokinetic Modeling , 2016, European Journal of Drug Metabolism and Pharmacokinetics.
[67] Jeffrey W Fisher,et al. Development of a physiologically based pharmacokinetic model for assessment of human exposure to bisphenol A. , 2015, Toxicology and applied pharmacology.
[68] M. Shimoda,et al. Pharmacokinetics of flunixin in the cat: enterohepatic circulation and active transport mechanism in the liver. , 2004, Journal of veterinary pharmacology and therapeutics.
[69] R. Gehring,et al. Development and application of a population physiologically based pharmacokinetic model for penicillin G in swine and cattle for food safety assessment. , 2017, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.
[70] M. Sheffer,et al. CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT , 2011 .
[71] Stephanie Läer,et al. A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows , 2015, Clinical Pharmacokinetics.
[72] L. Musib,et al. Pediatric Dose Selection and Utility of PBPK in Determining Dose , 2018, The AAPS Journal.
[73] Yu-Mei Tan,et al. Integration of Life-Stage Physiologically Based Pharmacokinetic Models with Adverse Outcome Pathways and Environmental Exposure Models to Screen for Environmental Hazards. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.
[74] B. Kukanich,et al. The construction and application of a population physiologically based pharmacokinetic model for methadone in Beagles and Greyhounds , 2018, Journal of veterinary pharmacology and therapeutics.